Loss of FXR, one of bile acid receptors, enlarged livers. Yes‐associated protein 1 (YAP1), a
dominant oncogene, promotes hepatocellular carcinoma (HCC). However, the relationship …

Background Yes-associated protein 1 (YAP1) is highly expressed in liver cancer and has
been used as an independent prognostic marker for hepatocellular carcinoma (HCC), while …

The Hippo/YAP pathway plays an important role in the development of cancers. Previous
studies have reported that bile acids can activate YAP (Yes Associated Protein) to promote …

Liver cancer has relatively few early symptoms and is usually diagnosed in the advanced
stage. Sorafenib is the only first-line anticancer drug approved by the Food and Drug …

Hepatocellular carcinoma (HCC) was the third most common cause of cancer death. But it
has only limited therapeutic options, aggressive nature, and very low overall survival …

For unresectable Hepatocellular carcinoma (HCC), chemotherapy is still an important
treatment strategy. Oxaliplatin (Oxa) is an effective treatment of HCC after sorafenib …

Yes-associated protein (YAP) is a transcriptional coactivator that promotes cell proliferation,
migration, and tissue homeostasis in colorectal cancer (CRC). Here, we established 5-Fu …

Isocitrate dehydrogenase (IDH) mutations increase (R)-2-hydroxyglutarate (R-2HG)
production; however, functional mechanisms of R-2HG in regulating cholangiocarcinoma …

Metformin plays an anti-proliferative role in tumor cells in many types of cancer. However,
the correlation between metformin and sensitivity to chemotherapeutic agents in …

The Yes‐associated protein (YAP)/Hippo pathway has been implicated in tissue
development, regeneration, and tumorigenesis. However, its role in cholangiocarcinoma …